A 79-year-old male with Parkinsonian-plus syndrome, what medications are appropriate for treating anxiety and insomnia?

Medication Recommendations for Anxiety and Insomnia in Parkinsonian-Plus Syndrome

For this 79-year-old male with Parkinsonian-plus syndrome, avoid benzodiazepines entirely and prioritize melatonin receptor agonists (ramelteon) for insomnia, with SSRIs (sertraline, citalopram) for anxiety, while recognizing that cognitive-behavioral therapy for insomnia (CBT-i) should be the first-line approach when feasible.

Critical Safety Considerations

The 2019 AGS Beers Criteria explicitly warns that benzodiazepines and benzodiazepine receptor agonists (z-drugs) substantially increase risk of falls, fractures, delirium, cognitive impairment, and mortality in older adults 1. This is particularly dangerous in Parkinsonian-plus syndromes where motor impairment and postural instability are already severe. The evidence is rated as "strong" - meaning harms clearly outweigh benefits 1.

Insomnia Management Algorithm

First-Line: Non-Pharmacologic

• Cognitive-behavioral therapy for insomnia (CBT-i) is the most effective first-line treatment with demonstrated safety in Parkinson's disease 2. Unlike medications, CBT-i has no adverse effects in already-weakened patients 2.
• Implement sleep hygiene: stable bed/wake times, avoid daytime napping after 2pm (limit to 30 minutes if needed), avoid caffeine/nicotine/alcohol, use bedroom only for sleep 3

Second-Line: Pharmacologic

If non-pharmacologic approaches fail:

Melatonin receptor agonist (ramelteon) is preferred because it shows no motor/cognitive impairment, no abuse potential, and maintains circadian rhythm 3. The 2009 JAGS guidelines specifically note that melatonin receptor agonists have "no significant effects indicative of potential for abuse or motor and cognitive impairment" 3.

Start at the lowest available dose - this is emphasized repeatedly in geriatric guidelines 3.

Avoid Completely

• All benzodiazepines (increase fall risk, cannot be recommended) 4, 5
• Z-drugs (zolpidem, eszopiclone, zaleplon) - while slightly safer than benzodiazepines, still carry substantial risks in this population 1
• Antihistamines, antipsychotics, anticonvulsants - no systematic evidence for effectiveness and risks outweigh benefits 3
• Trazodone - frequently prescribed but lacks evidence 3

Anxiety Management Algorithm

Optimize Dopaminergic Therapy First

Anxiety in Parkinson's disease often correlates with "off" periods and improves with levodopa 4. Before adding anxiolytics, optimize anti-parkinsonian medications to minimize motor fluctuations. Use levodopa with dopa decarboxylase inhibitor as the mainstay, potentially with COMT inhibitor if needed 6.

Pharmacologic Treatment for Persistent Anxiety

SSRIs are the preferred anxiolytic class based on:

• Relative freedom from side effects 5
• Modest but significant anxiolytic effect (standardized mean difference: -0.45, p=0.02) 7
• Can treat comorbid depression (present in 80% of PD patients with anxiety) 8

Specific SSRI selection:

• Sertraline or citalopram - best side effect profiles in elderly
• Avoid paroxetine - strong anticholinergic effects contraindicated in elderly 1

Alternative if SSRI not tolerated:

• Venlafaxine (SNRI) 5
• Mirtazapine - if insomnia or weight loss is prominent 5

Avoid in Parkinsonian-Plus Syndromes

• Benzodiazepines - despite being anxiolytic, they increase fall risk substantially 4, 5
• Tricyclic antidepressants - anticholinergic burden is particularly dangerous in Parkinsonian-plus syndromes which often have cognitive impairment 1

Special Considerations for Parkinsonian-Plus Syndromes

Parkinsonian-plus syndromes (MSA, PSP, CBD, DLB) differ from idiopathic Parkinson's disease:

• More severe motor impairment - fall risk is even higher
• Poorer response to dopaminergic therapy - but still worth optimizing 6
• Higher dementia risk - anticholinergic medications are particularly dangerous
• Greater autonomic dysfunction - avoid medications that worsen orthostatic hypotension

Practical Implementation

1. Start with sleep hygiene education and CBT-i referral 2
2. Optimize levodopa dosing to minimize "off" periods that trigger anxiety 4
3. If insomnia persists: Add ramelteon at lowest dose 3
4. If anxiety persists despite optimized dopaminergic therapy: Add sertraline or citalopram, starting at half the usual adult dose 5
5. Monitor closely for worsening motor symptoms, falls, confusion, or orthostatic hypotension

Common Pitfalls to Avoid

• Do not prescribe benzodiazepines even for short-term use - the fall and cognitive risks are too high 1, 4
• Do not use antipsychotics for anxiety (only for psychosis, and then only quetiapine, clozapine, or pimavanserin) 1
• Do not assume anxiety requires medication - it may resolve with better motor control 4
• Do not use medications "as needed" for anxiety - SSRIs require daily dosing; short-acting benzodiazepines should be avoided entirely 5

The evidence base for treating anxiety in Parkinson's disease remains limited, with no randomized trials using anxiety as a primary outcome 7, 4. However, the safety profile clearly favors SSRIs over benzodiazepines, and non-pharmacologic approaches should always be attempted first 2.